Clinical trial
Second-line Treatment in Patients With Small Cell Lung Cancer (SCLC)
NCT00418743 · Groupe Francais De Pneumo-Cancerologie, Other · Unknown status
Key facts
| NCT number | NCT00418743 |
|---|---|
| Title | Second-line Treatment in Patients With Small Cell Lung Cancer (SCLC) |
| Official title | A Phase II Randomised Trial of Second-line Treatment in Patients With Small Cell Lung Cancer (SCLC), Comparing Oral Combination Chemotherapy (CCNU, Cyclophosphamide, Etoposide) With Intravenous Association Chemotherapy. |
| Lead sponsor | Groupe Francais De Pneumo-Cancerologie, Other |
| Collaborators | Baxter Healthcare Corporation Industry Amgen |
| Status | Unknown status |
| Study type | Observational |
| Conditions | Small Cell Lung Cancer |
| Enrollment | 138 |
| Start date | Dec 1, 2005 |
| Completion | May 1, 2010 |
| First posted | Jan 5, 2007 |
| Last update posted | Mar 9, 2010 |
| Countries | France |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: